[
  {
    "ts": null,
    "headline": "Ozempic’s Maker Got Crushed. The Rebound Is Under Way.",
    "summary": "With a weight-loss pill on the horizon and the FDA’s signal of a tougher stance on compounded knockoffs, Novo Nordisk might be turning a corner.",
    "url": "https://finnhub.io/api/news?id=341acef416513ced8e3aab07a296ca8ad5913fde3b49df89a40780b0ceca3e3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758456000,
      "headline": "Ozempic’s Maker Got Crushed. The Rebound Is Under Way.",
      "id": 136836502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "With a weight-loss pill on the horizon and the FDA’s signal of a tougher stance on compounded knockoffs, Novo Nordisk might be turning a corner.",
      "url": "https://finnhub.io/api/news?id=341acef416513ced8e3aab07a296ca8ad5913fde3b49df89a40780b0ceca3e3a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Plans $5 Billion Virginia Facility to Boost Monoclonal Antibody Production",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in Goochland County, Virginia. This is the first of four new U.S. production locations that Eli Lilly & Company (NYSE:LLY) hopes to reveal […]",
    "url": "https://finnhub.io/api/news?id=84e80b57c6266390cee66d8782365c4bbd1c361358c01ca79b61b27642de4d1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758445889,
      "headline": "Eli Lilly (LLY) Plans $5 Billion Virginia Facility to Boost Monoclonal Antibody Production",
      "id": 136836503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in Goochland County, Virginia. This is the first of four new U.S. production locations that Eli Lilly & Company (NYSE:LLY) hopes to reveal […]",
      "url": "https://finnhub.io/api/news?id=84e80b57c6266390cee66d8782365c4bbd1c361358c01ca79b61b27642de4d1e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity",
    "summary": "Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.",
    "url": "https://finnhub.io/api/news?id=f97dd3c0f35cd08552c418c429ce689b9e3b0ebbca9ab0a6b35074cfc902c35c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758444285,
      "headline": "Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity",
      "id": 136834225,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230314692/image_2230314692.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.",
      "url": "https://finnhub.io/api/news?id=f97dd3c0f35cd08552c418c429ce689b9e3b0ebbca9ab0a6b35074cfc902c35c"
    }
  }
]